Caliway Biopharmaceuticals Co. L
6919
Rang in Aktien
#4342
Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated... Caliway Biopharmaceuticals Co., Ltd., and its affiliated entities, is dedicated to developing pharmaceuticals primarily in the fields of aesthetic medicine and chronic inflammation. Its lead investigational drug, CBL-514, is currently undergoing Phase 2 clinical trials, targeting non-surgical fat reduction, Dercum's disease, and cellulite. Beyond this, the firm is also progressing CBA-539 through preclinical exploration for potential applications in central obesity, hyperpigmentation, and skin aging. The company's offerings also extend to dietary supplements. Established in 2012, Caliway Biopharmaceuticals operates from its headquarters in New Taipei City, Taiwan.
Aktienkurs
$2.29
Marktkapitalisierung
$3.56B
Veränderung (1 Tag)
-2.50%
Veränderung (1 Jahr)
-57.22%
Land
TW
Handel Caliway Biopharmaceuticals Co. L (6919)
Kategorie
Healthcare
EPS für Caliway Biopharmaceuticals Co. L (6919)
EPS zum 2026 TTM: 0
Laut den aktuellen Finanzberichten und dem Aktienkurs von Caliway Biopharmaceuticals Co. L beträgt das aktuelle EPS des Unternehmens (TTM) 0. Am Ende des Jahres 2026 betrug das EPS 0 gleich wie dem EPS von 2026, das 0 betrug.
EPS-Verlauf von Caliway Biopharmaceuticals Co. L von 2019 bis 2026
EPS am Ende jedes Jahres
| Jahr | EPS | ändert |
|---|---|---|
| 2025 | $-0.01 | -41.60% |
| 2024 | $-0.01 | -1.57% |
| 2023 | $-0.01 | 62.82% |
| 2022 | $-0.01 | -10.34% |
| 2021 | $-0.01 | 89.13% |
| 2020 | 0.00 | -19.30% |
| 2019 | $-0.01 | 0.00% |
EPS für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | EPS | EPS-Differenz | Land |
|---|---|---|---|
| $17.32 | - |
US
|
|
| $-7.98 | - |
US
|
|
| $-5.29 | - |
AU
|
|
| $27.74 | - |
NL
|
|
| - | - |
CH
|
